Study of ONO-8539 in Patients With Overactive Bladder

Ono Pharmaceutical Co., Ltd.435 enrolled

Overview

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

435

Conditions

Overactive Bladder

Interventions

PlaceboDRUG

Placebo / 12 weeks

TolterodineDRUG

4mg / 12 weeks

ONO-8539DRUG

low dose / 12 weeks

ONO-8539

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with medical history of Overactive Bladder symptoms for \> 6 months Exclusion Criteria: * Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results

Locations (50)

Outcomes

Primary Outcomes

Overactive bladder symptoms

Time frame: 12 weeks

Secondary Outcomes

Overactive bladder symptoms (QOL)

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Brno, Czechia

Unnamed facility

Jindřichův Hradec, Czechia

Unnamed facility

Olomouc, Czechia

Unnamed facility

Opava, Czechia

Unnamed facility

Pilsen, Czechia

Unnamed facility

Prague, Czechia

Unnamed facility

Štětí, Czechia

Unnamed facility

Ústí nad Labem, Czechia

Unnamed facility

Duisburg, Germany

Unnamed facility

Hagenow, Germany

...and 40 more locations